Beth Israel Deaconess Medical Center (BIDMC) Joins Precision Biologics as Collaborators on Phase 2B Pancreatic Cancer Trial

Precision Biologics is pleased to announce the addition of Beth Israel Deaconess (BIDMC)as a collaborator on its ongoing Phase 2 clinical trial with its lead therapeutic compound NPC-1C (NEO-102). The randomized, multicenter Phase 2b clinical trial is currently accruing patients with metastatic pancreatic cancer who have progressed after front line chemotherapy with Folfirinox. The study combines second line Gemcitabine and Abraxane chemotherapy with or without NPC-1C. BIDMC will be joining the current clinical sites on this multicenter study, including National Cancer Institute, Yale Cancer Center, Medical Dana-Farber/Harvard Cancer Center (DF/HCC), Massachusetts General Hospital (MGH), Sidney Kimmel Cancer Center at Thomas Jefferson University, Rutgers-Cancer Institute of New Jersey, UTSW Medical Center, Washington University in St. Louis, and Duke University Medical Center in partnership with Precision Biologics.

Contacts

Precision Biologics
Press:
Sophia Lall
(c) 718-483-0735
(o) 212-414-1909
slall@rmtprmanagement.com
or
RoseMarie Terenzio
(c) 917-913-7226
(o) 212-414-1909
rterenzio@rmtprmanagement.com